Department of Neurology
The Department of Neurology at the University of California, Davis conducts basic and clinical research on the nervous system and provides clinical care for people with neurological disorders, such as Alzheimer's disease and other forms of dementia, epilepsy, movement disorders like Parkinson's and Huntington's diseases, tremor, dystonia, multiple sclerosis, neuromuscular conditions, headache, and sleep disorders.
The department’s faculty includes leading neuroscientists, who work to expand our knowledge of nervous system function, as well as neurologists and psychologists who provide diagnosis and treatment for adults and children. The department offers cutting-edge diagnostic approaches, including advanced neuroimaging technologies, and access to trials of new medications and other therapeutic modalities.
The department's educational programs include medical student training, an active residency program that enrolls 15 residents, and several post-doctoral fellowships in clinical neurophysiology, clinical neuropsychology, epilepsy, movement disorders, and neurodegeneration and aging.
Faculty Research Highlights
Community-Engaged Research to Reduce Alzheimer’s Disease-Related Disparities. Oanh Meyer of UC Davis focuses on Alzheimer's Disease related disparities in the Vietnamese American Community, working with nonproficts and caregivers. She is "currently studying the experiences of caregivers and how programs may help improve their lives, which she believes is understudied for Asian Americans."
Robotic Exoskeleton for the Stabilization of Tremors (RST) in the Hand and Wrist. (PDF) Lin Zhang of UC Davis and Gabriel Elkaim of the UC Santa Cruz College of Engineering have received a 2016 CITRIS Seed Fund Award to develop their novel solution for millions of Americans living with Parkinson’s disease or Essential Tremor.
Human stem cells target Huntington's disease. Vicki Wheelock is working with UC Davis stem cell researchers to develop a treatment for Huntington's disease (HD). Their research into mesenchymal stem cells engineered to overproduce brain-derived neurotropic factor (BDNF) shows diminished neuron loss, reduced symptoms, and extended life in animal models of HD.
Ricardo Maselli has received a $300,000 grant from the Muscular Dystophy Association to test the use of stem cells to deliver ColQ, a protein that is deficient in a severe form of congenital myasthenic syndrome.